Interstitial Lung Disease without CC/MCC DRG Reimbursement

DRG 198 encompasses inpatient cases of interstitial lung disease without a Complication or Comorbidity or Major Complication or Comorbidity, defining a lower-resource clinical subgroup for payment. Proper assignment matters for inpatient reimbursement because it determines base Medicare payment and resource categorization for hospitals.

DRG 198 Overview

DRG 198 covers inpatient admissions for interstitial lung disease without a Complication or Comorbidity or Major Complication or Comorbidity present. It includes conditions such as idiopathic pulmonary fibrosis and other diffuse parenchymal lung diseases when the clinical course is uncomplicated by additional major diagnoses. This Diagnosis-Related Group matters for Medicare payment because it groups similar resource use and influences base reimbursement for hospitals caring for these patients. Accurate coding and documentation of comorbid conditions determine whether cases remain in this DRG or escalate to higher-paying groups.

Acute inpatient therapeutic trials testing anti-inflammatory or antifibrotic strategies aimed at reducing respiratory failure and need for prolonged mechanical ventilation in hospitalized patients with acute exacerbations of interstitial lung disease (ILD). These studies enroll patients admitted with acute worsening of ILD symptoms, often hypoxemia or new infiltrates on imaging, and assess short-term endpoints such as time to wean from oxygen or ventilator, ICU length of stay, and in-hospital mortality. This research is directly relevant to providers and payers because preventing progression to respiratory failure can shorten high-cost inpatient stays, reduce use of critical care resources, and improve discharge disposition.
Comparative effectiveness studies evaluating diagnostic and management pathways for hospitalized ILD patients without major complications (no CC/MCC), such as early high-resolution CT plus multidisciplinary consultation versus standard workup, or different corticosteroid strategies. These trials focus on patients admitted for new or worsening dyspnea attributable to ILD but who do not meet severity thresholds that define CC/MCC, measuring outcomes like diagnostic yield, length of stay, readmission rates, and functional status at discharge. Payers and hospital administrators benefit from evidence identifying efficient care pathways that optimize resource use while ensuring accurate diagnosis and appropriate treatment intensity for this mid-acuity population.
Post-discharge outcomes and care-transition studies examining rehabilitation, outpatient monitoring, and readmission prevention for patients discharged after hospitalization for ILD without CC/MCC. These pragmatic studies follow patients after discharge to evaluate interventions such as structured pulmonary rehabilitation, telemonitoring of oxygen needs, or coordinated outpatient specialist follow-up, with outcomes including 30- and 90-day readmissions, outpatient utilization, and patient-reported respiratory function. For providers and payers, improving post-discharge management can reduce costly readmissions, support better long-term functional outcomes, and inform bundled payment or case management strategies for this DRG.

Acute inpatient therapeutic trials testing anti-inflammatory or antifibrotic strategies aimed at reducing respiratory failure and need for prolonged mechanical ventilation in hospitalized patients with acute exacerbations of interstitial lung disease (ILD). These studies enroll patients admitted with acute worsening of ILD symptoms, often hypoxemia or new infiltrates on imaging, and assess short-term endpoints such as time to wean from oxygen or ventilator, ICU length of stay, and in-hospital mortality. This research is directly relevant to providers and payers because preventing progression to respiratory failure can shorten high-cost inpatient stays, reduce use of critical care resources, and improve discharge disposition.
Comparative effectiveness studies evaluating diagnostic and management pathways for hospitalized ILD patients without major complications (no CC/MCC), such as early high-resolution CT plus multidisciplinary consultation versus standard workup, or different corticosteroid strategies. These trials focus on patients admitted for new or worsening dyspnea attributable to ILD but who do not meet severity thresholds that define CC/MCC, measuring outcomes like diagnostic yield, length of stay, readmission rates, and functional status at discharge. Payers and hospital administrators benefit from evidence identifying efficient care pathways that optimize resource use while ensuring accurate diagnosis and appropriate treatment intensity for this mid-acuity population.
Post-discharge outcomes and care-transition studies examining rehabilitation, outpatient monitoring, and readmission prevention for patients discharged after hospitalization for ILD without CC/MCC. These pragmatic studies follow patients after discharge to evaluate interventions such as structured pulmonary rehabilitation, telemonitoring of oxygen needs, or coordinated outpatient specialist follow-up, with outcomes including 30- and 90-day readmissions, outpatient utilization, and patient-reported respiratory function. For providers and payers, improving post-discharge management can reduce costly readmissions, support better long-term functional outcomes, and inform bundled payment or case management strategies for this DRG.

OpenPayer

Summary & Overview

Interstitial Lung Disease without CC/MCC: Inpatient Reimbursement Overview

DRG 198 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes